Durable disease control has been observed in a minority of patients due to immunotherapy, says Weiss. With the newer therapies of PD-1/PD-L1 both alone and in combination with CTLA-4 inhibitors and other agents, higher rates of disease control is being seen than previously.

Only a small number of patients achieve what appears to be a cure, but immunotherapy is a bigger step in the evolution of cancer care. Many people are thriving longer with lower toxicities but a cure still needs to be researched, explains Weiss.

Durable disease control has been observed in a minority of patients due to immunotherapy, says Weiss. With the newer therapies of PD-1/PD-L1 both alone and in combination with CTLA-4 inhibitors and other agents, higher rates of disease control is being seen than previously.

Only a small number of patients achieve what appears to be a cure, but immunotherapy is a bigger step in the evolution of cancer care. Many people are thriving longer with lower toxicities but a cure still needs to be researched, explains Weiss.